Published in Am J Clin Oncol on June 01, 1984
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol (2003) 5.71
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. J Vasc Surg (1998) 2.39
Temperature and Excitability. J Physiol (1896) 2.21
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun (1970) 1.79
Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms. J Vasc Surg (2000) 1.77
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol (2002) 1.62
Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol (1996) 1.59
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol (1993) 1.52
Timing of postcarotid complications: a guide to safe discharge planning. J Vasc Surg (2001) 1.42
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Lymphography in carcinoma of the uterus. Clin Radiol (1972) 1.38
Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res (2000) 1.37
Role of lymphography in carcinoma of the prostate. Br Med J (1975) 1.34
Observations on the growth of tumours in lymph nodes changing from normal to abnormal while remaining opacified after lymphography. Clin Radiol (1968) 1.31
The role of computed tomography in the management of testicular teratoma. Clin Radiol (1979) 1.28
delta 9-tetrahydrocannabinol in clinical oncology. JAMA (1981) 1.23
Early thrombus remodelling of isolated calf deep vein thrombosis. Eur J Vasc Endovasc Surg (2002) 1.21
The value of lymphography to the radiotherapist. Clin Radiol (1969) 1.20
Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol (1990) 1.19
New insights into perforator vein incompetence. Eur J Vasc Endovasc Surg (1999) 1.18
Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol (1996) 1.08
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol (1997) 1.07
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer (1981) 1.07
Cutaneous seeding of pancreatic cancer by skinny-needle aspiration biopsy. Arch Intern Med (1980) 1.05
Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. J Clin Oncol (1987) 1.04
Compensatory arterial enlargement is a common pathobiologic response in early atherosclerosis. Am J Surg (1998) 1.00
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol (2002) 0.99
Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol (1997) 0.98
Lymphography in carcinoma of the ovary. Proc R Soc Med (1971) 0.97
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer (1994) 0.97
Lymphography in malignant disease of the urinary tract. Proc R Soc Med (1970) 0.97
p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol (1999) 0.96
Phase-II trial of tamoxifen in advanced breat cancer. Cancer Chemother Pharmacol (1979) 0.95
Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial. Cancer (1978) 0.94
Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol (1995) 0.94
Nonsaphenous superficial vein reflux. J Vasc Surg (2001) 0.94
Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer (1978) 0.93
Patterns and distribution of isolated calf deep vein thrombosis. J Vasc Surg (1999) 0.92
Phase I clinical trial of spirogermanium. Cancer Treat Rep (1981) 0.91
Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol (1982) 0.91
Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant (1994) 0.91
Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. Blood (1978) 0.91
Lymphography in the management of urinary tract tumours. Br J Urol (1968) 0.90
An introduction to current controversies in cancer management: stage I testicular cancer-a case in point. Cancer Treat Rep (1982) 0.89
Augmentation of blood flow in limbs with occlusive arterial disease by intermittent calf compression. J Vasc Surg (1994) 0.89
Adjuvant therapy in colorectal carcinoma. Semin Oncol (1991) 0.88
Chemotherapy of colorectal carcinoma. Semin Oncol (1976) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer (1993) 0.87
Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. Surgery (1999) 0.86
The impact of isolated lesser saphenous vein system incompetence on clinical signs and symptoms of chronic venous disease. J Vasc Surg (2000) 0.86
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol (1987) 0.86
Where does venous reflux start? J Vasc Surg (1997) 0.86
Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs (1988) 0.85
Postburn immunosuppression in an animal model. IV. Improved resistance to septic challenge with immunomodulating drugs. Surgery (1986) 0.85
Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol (1978) 0.84
Radical cystectomy for carcinoma of the bilharzial bladder. Br J Urol (1972) 0.84
Radical cystectomy for carcinoma of bilharzial bladder. Technique and results. Urology (1976) 0.84
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma. Biochem Pharmacol (1981) 0.83
The accuracy of lymphography in Hodgkin's disease. Clin Radiol (1974) 0.83
Local anesthesia for infrainguinal arterial reconstruction. Am J Surg (1997) 0.83
Carcinoma of the bilharzial urinary bladder. A study of the associated mucosal lesions in 86 cases. Cancer (1972) 0.83
Mitomycin therapy in gastric cancer. Oncology (1993) 0.82
Breast cancer in Arabic women. Oncology (1982) 0.82
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer (1995) 0.82
Hypocalcemia associated with a calcitonin-producing hepatocellular carcinoma. Arch Intern Med (1981) 0.82
Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009. Cancer Immunol Immunother (1999) 0.82
A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J Biol Response Mod (1990) 0.81
Carcinoma of the bilharzial bladder in Egypt. Clinical and pathological features. Br J Urol (1972) 0.81
Prevalence of deep venous reflux in patients with primary superficial vein incompetence. J Vasc Surg (2000) 0.81
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer (1996) 0.80
Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). Adv Exp Med Biol (1993) 0.80
Verrucose squamous carcinoma of bladder. Urology (1974) 0.80
Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26. Cancer Treat Rep (1978) 0.80
Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant (1997) 0.80
Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs (1997) 0.80
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules. Cancer (1993) 0.80
Computed tomography in testicular disease: a review. J R Soc Med (1981) 0.80
Hepatic estrogen and progesterone receptors in an estrogen-associated hepatic neoplasm. Cancer Chemother Pharmacol (1978) 0.80
Intra-aortic balloon counterpulsation in patients with severe cardiac dysfunction undergoing abdominal operations. Arch Surg (1998) 0.79
Primary superficial vein reflux with competent saphenous trunk. Eur J Vasc Endovasc Surg (1999) 0.79
A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother (1991) (1991) 0.79
Continuous low-dose infusion of fluorouracil: is the benefit worth the cost? J Clin Oncol (1989) 0.79
A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann Oncol (1991) 0.79
Computed tomography applied to radiotherapy treatment planning: techniques and results. Radiology (1979) 0.79